Isis Pharmaceuticals receives another antisense patent

By Elaine Rigoli

Tampa, Fla., March 27 - Isis Pharmaceuticals, Inc. announced the issuance of U.S. Patent No. 7,015,315 by the U.S. Patent and Trademark Office.

This patent covers antisense drugs with modified sugars, frequently called "chimeric" oligonucleotides or "gapmers," including Isis' proprietary second-generation chemistry, generation 2.2 chemistry and other sugar-modified antisense compounds, according to a news release.

Isis said this patent, one of several hundred U.S. patents issued to the company that cover the chemistry and design of antisense compounds, extends the patent life of its second-generation antisense drugs.

This newly issued patent expires March 2023, the release said.

Isis and its partners currently have 12 second-generation antisense drugs in clinical development that are covered by the '315 U.S. Patent.

Isis is the owner or exclusive licensee of about 1,500 issued patents worldwide.

Carlsbad, Calif.-based Isis is an RNA-based drug discovery and development company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.